

Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P.

Purdue Pharma L.P. has recalculated its 340B ceiling prices for the period from Q4 2016 through Q2 2017 for various products, and due to a new product launch for Symproic® Tablets, for time periods Q4 2017 through Q2 2018. Products whose ceiling price were impacted by revisions to their Medicaid pricing data are listed below. Also listed are the relevant 340B ceiling price quarters for which the ceiling price of that product was impacted. Purdue has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the HRSA public website to ensure transparency by providing access to information about Purdue’s recalculation affecting certain 340B Covered Entities for the impacted Purdue product.

Purdue has determined the credit amount owed to each affected covered entity. Purdue will be working with Apexus, LLC (“Apexus”), the 340B Prime Vendor, to validate wholesaler pharmacy account information for each affected Covered Entity. If a wholesaler account is identified, Purdue will issue a credit to the Covered Entity through the wholesaler, and a check will be issued to Covered Entities whose wholesaler account cannot be identified. If a Covered Entity believes they are due a refund and are not contacted by Apexus within a month after the posting of this notice, you may contact Alicia Graziano, Purdue Pharma L.P. Director of Government and Institutional Contract Ops, at Alicia.Graziano@pharma.com.

<u>NDC</u>	<u>Product Description</u>	<u>Relevant Period</u>
59011-0255-30	INTERMEZZO® 3.5MG (zolpidem tartrate) SUBLINGUAL TABLETS C-IV	Q4 2016 - Q2 2017
59011-0256-30	INTERMEZZO® 1.75MG (zolpidem tartrate) SUBLINGUAL TABLETS C-IV	Q4 2016 - Q2 2017
59011-0271-60	HYSINGLA® ER 20MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q4 2016 - Q2 2017
59011-0272-60	HYSINGLA® ER 30MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q4 2016 - Q2 2017
59011-0273-60	HYSINGLA® ER 40MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q4 2016 - Q2 2017
59011-0274-60	HYSINGLA ER® 60MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q4 2016 - Q2 2017
59011-0275-60	HYSINGLA ER® 80MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q4 2016, Q1 2017
59011-0276-60	HYSINGLA® ER 100MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q1 2017
59011-0277-60	HYSINGLA® ER 120MG (hydrocodone bitartrate) EXTENDED-RELEASE TABLETS C-II	Q1 2017, Q2 2017
59011-0451-01	DILAUDID® (hydromophone hydrochloride) ORAL LIQUID C-II, 473mL bottle	Q4 2016, Q1 2017
59011-0452-10	DILAUDID® 2MG (hydromophone hydrochloride) TABLETS C-II, 100ct	Q4 2016, Q2 2017
59011-0454-01	DILAUDID® 4MG (hydromophone hydrochloride) UNIT DOSE C-II	Q2 2017

<u>NDC</u>	<u>Product Description</u>	<u>Relevant Period</u>
59011-0454-10	DILAUDID® 4MG (hydromophone hydrochloride) TABLETS C-II, 100ct	Q4 2016 - Q2 2017
59011-0458-10	DILAUDID® 8MG (hydromophone hydrochloride) TABLETS C-II, 100ct	Q4 2016, Q1 2017
59011-0750-04	BUTRANS® 5 MCG/HOUR (buprenorphine) TRANSDERMAL SYSTEM C-III	Q1 2017, Q2 2017
59011-0751-04	BUTRANS® 10 MCG/HOUR (buprenorphine) TRANSDERMAL SYSTEM C-III	Q1 2017, Q2 2017
59011-0752-04	BUTRANS® 20 MCG/HOUR (buprenorphine) TRANSDERMAL SYSTEM C-III	Q1 2017, Q2 2017
59011-0757-04	BUTRANS® 7.5 MCG/HOUR (buprenorphine) TRANSDERMAL SYSTEM C-III	Q4 2016 - Q2 2017
59011-0758-04	BUTRANS® 15 MCG/HOUR (buprenorphine) TRANSDERMAL SYSTEM C-III	Q2 2017
67618-0150-08	BETADINE (povidone-iodine) 10% FIRST AID SOLUTION - OTC , 8oz Bottle	Q2 2017
67618-0151-04	BETADINE (povidone-iodine) 7.5% SURGICAL SCRUB, 4oz bottle	Q2 2017
67618-0200-04	BETASEPT (chlorhexidine gluconate) 4% ANTISEPTIC SURGICAL SCRUB, 4oz Bottle	Q4 2016 - Q2 2017
67618-0200-08	BETASEPT (chlorhexidine gluconate) 4% ANTISEPTIC SURGICAL SCRUB, 8oz Bottle	Q4 2016 - Q2 2017
67618-0200-16	BETASEPT (chlorhexidine gluconate) 4% ANTISEPTIC SURGICAL SCRUB, 16oz Bottle	Q1 2017, Q2 2017
59011-0523-90	SYMPROIC® 0.2MG (naldemedine) TABLETS, 90ct	Q1 2018, Q2 2018
59011-0523-30	SYMPROIC® 0.2MG (naldemedine) TABLETS, 30ct	Q2 2018